



## SVB Securities Serves as Financial Advisor to Lantheus (NASDAQ: LNTH) on its Exclusive Licensing Agreements with Point Biopharma (NASDAQ: PNT)

### Key Transaction Highlights

- On November 16, 2022, Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH) and Point Biopharma Global Inc. ("Point") (NASDAQ: PNT) announced a set of strategic collaborative agreements in which Lantheus will license exclusive worldwide rights to Point's PNT202 and PNT203 product candidates.
- The agreements expand Lantheus' oncology pharmaceutical portfolio with two late-stage therapeutic candidates and, with PNT202, increases Lantheus' oncology product portfolio.
- For PNT202, the agreement puts PNT202 and PNT203 with an equal commercialization partner, and effects brand and marketing roles, while still maintaining the roles and independence of Point's next-generation oncology platform.
- PNT202 is a PD-L1 targeted <sup>177</sup>Lu-labeled radiopharmaceutical therapy for metastatic castration-resistant prostate cancer (mCRPC) and currently is in Phase 3 SPURR study.
- PNT203 is a second-line receptor tyrosine kinase targeted radioligand therapy with no-carrier added <sup>177</sup>Lu in development for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and currently is in Phase 3 SPURR-2 study.

### About Lantheus

With more than 35 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through Biopharmaceutical, radiopharmaceutical and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden.

### About Point Biopharma

Point Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligand therapies for cancer. Point aims to maximize patient outcomes by combining a portfolio of radiopharmaceutical assets, a seasoned management team, an industry leading pipeline, in-house manufacturing capabilities, and received equity for two critical features: the extensive oncology and nuclear medicine (NM) pipeline. Point's cancer pipeline includes PNT202 for Phase 3 trial for mCRPC, a pan-cancer program targeting fibroblast activation protein (FAP), and SPURR for Phase 3 trial for PNT203 for gastric NET. Lantheus will commercialize mCRPC product candidate prostate cancer (mCRPC) after second line hormonal treatment.

For more information, please contact Andrew Jain at [ajain@svb.com](mailto:ajain@svb.com). For more information, please contact Kevin O'Connell at [koconnell@svb.com](mailto:koconnell@svb.com).

SECURITIES AND FINANCIAL SERVICES: INVESTMENT BANKING AND FINANCIAL ADVISORY SERVICES. SVB FINANCIAL GROUP, INC. (NASDAQ: SVBF) IS A FINANCIAL SERVICES COMPANY THAT PROVIDES A FULL RANGE OF FINANCIAL SERVICES TO BANKING, FINANCIAL SERVICES AND OTHER INSTITUTIONAL CLIENTS. SVB FINANCIAL GROUP, INC. IS A FINANCIAL SERVICES COMPANY THAT PROVIDES A FULL RANGE OF FINANCIAL SERVICES TO BANKING, FINANCIAL SERVICES AND OTHER INSTITUTIONAL CLIENTS.

SVB FIN  
 100 Pine Street  
 San Francisco, CA 94111

SVB FIN  
 100 Pine Street  
 San Francisco, CA 94111

SVB FIN  
 100 Pine Street  
 San Francisco, CA 94111

SVB FIN  
 100 Pine Street  
 San Francisco, CA 94111

SVB FIN  
 100 Pine Street  
 San Francisco, CA 94111